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Abstract
The mission of the Encyclopedia of DNA Elements (ENCODE) Project is to enable the scientific and medical communities to
interpret the human genome sequence and apply it to understand human biology and improve health. The ENCODE
Consortium is integrating multiple technologies and approaches in a collective effort to discover and define the functional
elements encoded in the human genome, including genes, transcripts, and transcriptional regulatory regions, together with
their attendant chromatin states and DNA methylation patterns. In the process, standards to ensure high-quality data have
been implemented, and novel algorithms have been developed to facilitate analysis. Data and derived results are made
available through a freely accessible database. Here we provide an overview of the project and the resources it is generating
and illustrate the application of ENCODE data to interpret the human genome.
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I. Introduction and Project Overview
Interpreting the human genome sequence is one of the leading
challenges of 21st century biology [1]. In 2003, the National
Human Genome Research Institute (NHGRI) embarked on an
ambitious project—the Encyclopedia of DNA Elements (EN-
CODE)—aiming to delineate all of the functional elements
encoded in the human genome sequence [2]. To further this
goal, NHGRI organized the ENCODE Consortium, an interna-
tional group of investigators with diverse backgrounds and
expertise in production and analysis of high-throughput functional
genomic data. In a pilot project phase spanning 2003–2007, the
Consortium applied and compared a variety of experimental and
computational methods to annotate functional elements in a
defined 1% of the human genome [3]. Two additional goals of the
pilot ENCODE Project were to develop and advance technologies
for annotating the human genome, with the combined aims of
achieving higher accuracy, completeness, and cost-effective
throughput and establishing a paradigm for sharing functional
genomics data. In 2007, the ENCODE Project was expanded to
study the entire human genome, capitalizing on experimental and
computational technology developments during the pilot project
period. Here we describe this expanded project, which we refer to
throughout as the ENCODE Project, or ENCODE.
The major goal of ENCODE is to provide the scientific
community with high-quality, comprehensive annotations of
candidate functional elements in the human genome. For the
purposes of this article, the term ‘‘functional element’’ is used to
denote a discrete region of the genome that encodes a defined
product (e.g., protein) or a reproducible biochemical signature,
such as transcription or a specific chromatin structure. It is now
widely appreciated that such signatures, either alone or in
combinations, mark genomic sequences with important functions,
including exons, sites of RNA processing, and transcriptional
regulatory elements such as promoters, enhancers, silencers, and
insulators. However, it is also important to recognize that while
certain biochemical signatures may be associated with specific
functions, our present state of knowledge may not yet permit
definitive declaration of the ultimate biological role(s), function(s),
or mechanism(s) of action of any given genomic element.
At present, the proportion of the human genome that encodes
functional elements is unknown. Estimates based on comparative
genomic analyses suggest that 3%–8% of the base pairs in the
human genome are under purifying (or negative) selection [4–7].
However, this likely underestimates the prevalence of functional
features, as current comparative methods may not account for
lineage-specific evolutionary innovations, functional elements that
are very small or fragmented [8], elements that are rapidly
evolving or subject to nearly neutral evolutionary processes, or
elements that lie in repetitive regions of the genome.
The current phase of the ENCODE Project has focused on
completing two major classes of annotations: genes (both
protein-coding and non-coding) and their RNA transcripts,
and transcriptional regulatory regions. To accomplish these
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goals, seven ENCODE Data Production Centers encompassing
27 institutions have been organized to focus on generating
multiple complementary types of genome-wide data (Figure 1
and Figure S1). These data include identification and
quantification of RNA species in whole cells and in sub-cellular
compartments, mapping of protein-coding regions, delineation
of chromatin and DNA accessibility and structure with
nucleases and chemical probes, mapping of histone modifica-
tions and transcription factor (TF) binding sites by chromatin
immunoprecipitation (ChIP), and measurement of DNA
methylation (Figure 2 and Table 1). In parallel with the major
production efforts, several smaller-scale efforts are examining
long-range chromatin interactions, localizing binding proteins
on RNA, identifying transcriptional silencer elements, and
understanding detailed promoter sequence architecture in a
subset of the genome (Figure 1 and Table 1).
ENCODE has placed emphasis on data quality, including
ongoing development and application of standards for data
reproducibility and the collection of associated experimental
information (i.e., metadata). Adoption of state-of-the-art, massively
parallel DNA sequence analysis technologies has greatly facilitated
standardized data processing, comparison, and integration [9,10].
Primary and processed data, as well as relevant experimental
methods and parameters, are collected by a central Data
Coordination Center (DCC) for curation, quality review, visual-
ization, and dissemination (Figure 1). The Consortium releases
data rapidly to the public through a web-accessible database
(http://genome.ucsc.edu/ENCODE/) [11] and provides a visu-
alization framework and analytical tools to facilitate use of the data
[12], which are organized into a web portal (http://encodeproject.
org).
To facilitate comparison and integration of data, ENCODE
data production efforts have prioritized selected sets of cell types
(Table 2). The highest priority set (designated ‘‘Tier 1’’) includes
two widely studied immortalized cell lines—K562 erythroleu-
kemia cells [13]; an EBV-immortalized B-lymphoblastoid line
(GM12878, also being studied by the 1,000 Genomes Project;
http://1000genomes.org) and the H1 human embryonic stem cell
line [14]. A secondary priority set (Tier 2) includes HeLa-S3
cervical carcinoma cells [15], HepG2 hepatoblastoma cells [16],
and primary (non-transformed) human umbilical vein endothelial
cells (HUVEC; [17]), which have limited proliferation potential in
culture. To capture a broader spectrum of human biological
diversity, a third set (Tier 3) currently comprises more than 100
cell types that are being analyzed in selected assays (Table 2).
Standardized growth conditions for all ENCODE cell types have
been established and are available through the ENCODE web
portal (http://encodeproject.org, ‘‘cell types’’ link).
This report is intended to provide a guide to the data and
resources generated by the ENCODE Project to date on Tier 1–3
cell types. We summarize the current state of ENCODE by
describing the experimental and computational approaches used
to generate and analyze data. In addition, we outline how to access
datasets and provide examples of their use.
II. ENCODE Project Data
The following sections describe the different types of data being
produced by the ENCODE Project (Table 1).
Genes and Transcripts
Gene annotation. A major goal of ENCODE is to annotate
all protein-coding genes, pseudogenes, and non-coding transcribed
loci in the human genome and to catalog the products of
transcription including splice isoforms. Although the human
genome contains ,20,000 protein-coding genes [18], accurate
identification of all protein-coding transcripts has not been
straightforward. Annotation of pseudogenes and noncoding
transcripts also remains a considerable challenge. While auto-
matic gene annotation algorithms have been developed, manual
curation remains the approach that delivers the highest level of
accuracy, completeness, and stability [19]. The ENCODE
Consortium has therefore primarily relied on manual curation
with moderate implementation of automated algorithms to produce
gene and transcript models that can be verified by traditional
experimental and analytical methods. This annotation process
involves consolidation of all evidence of transcripts (cDNA, EST
sequences) and proteins from public databases, followed by building
gene structures based on supporting experimental data [20]. More
than 50% of annotated transcripts have no predicted coding
potential and are classified by ENCODE into different transcript
categories. A classification that summarizes the certainty and types
of the annotated structures is provided for each transcript (see
http://www.gencodegenes.org/biotypes.html for details). The
annotation also includes extensive experimental validation by RT-
PCR for novel transcribed loci (i.e., those not previously observed
and deposited into public curated databases such as RefSeq).
Pseudogenes are identified primarily by a combination of similarity
to other protein-coding genes and an obvious functional
disablement such as an in-frame stop codon. Because it is difficult
to validate pseudogenes experimentally, three independent
annotation methods from Yale (‘‘pseudopipe’’) [21], UCSC
(‘‘retrofinder’’; http://users.soe.ucsc.edu/,markd/gene-sets-new/
pseudoGenes/RetroFinder.html, and references therein), and the
Sanger Center [20] are combined to produce a consensus
pseudogene set. Ultimately, each gene or transcript model is
assigned one of three confidence levels. Level 1 includes genes
validated by RT-PCR and sequencing, plus consensus pseudogenes.
Level 2 includes manually annotated coding and long non-coding
loci that have transcriptional evidence in EMBL/GenBank. Level 3
includes Ensembl gene predictions in regions not yet manually
annotated or for which there is new transcriptional evidence.
Author Summary
The Encyclopedia of DNA Elements (ENCODE) Project was
created to enable the scientific and medical communities
to interpret the human genome sequence and to use it to
understand human biology and improve health. The
ENCODE Consortium, a large group of scientists from
around the world, uses a variety of experimental methods
to identify and describe the regions of the 3 billion base-
pair human genome that are important for function. Using
experimental, computational, and statistical analyses, we
aimed to discover and describe genes, transcripts, and
transcriptional regulatory regions, as well as DNA binding
proteins that interact with regulatory regions in the
genome, including transcription factors, different versions
of histones and other markers, and DNA methylation
patterns that define states of the genome in various cell
types. The ENCODE Project has developed standards for
each experiment type to ensure high-quality, reproducible
data and novel algorithms to facilitate analysis. All data
and derived results are made available through a freely
accessible database. This article provides an overview of
the complete project and the resources it is generating, as
well as examples to illustrate the application of ENCODE
data as a user’s guide to facilitate the interpretation of the
human genome.
A User’s Guide to ENCODE
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The result of ENCODE gene annotation (termed ‘‘GENCODE’’)
is a comprehensive catalog of transcripts and gene models. ENCODE
gene and transcript annotations are updated bimonthly and are
available through the UCSC ENCODE browser, distributed
annotation servers (DAS; see http://genome.ucsc.edu/cgi-bin/das/
hg18/features?segment=21:33031597,
33041570;type=wgEncodeGencodeManualV3), and the Ensembl
Browser [22].
RNA transcripts. ENCODE aims to produce a compre-
hensive genome-wide catalog of transcribed loci that characterizes
the size, polyadenylation status, and subcellular compartmen-
talization of all transcripts (Table 1).
Figure 1. The Organization of the ENCODE Consortium. (A) Schematic representation of the major methods that are being used to detect
functional elements (gray boxes), represented on an idealized model of mammalian chromatin and a mammalian gene. (B) The overall data flow from
the production groups after reproducibility assessment to the Data Coordinating Center (UCSC) for public access and to other public databases. Data
analysis is performed by production groups for quality control and research, as well as at a cross-Consortium level for data integration.
doi:10.1371/journal.pbio.1001046.g001
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ENCODE has generated transcript data with high-density
(5 bp) tiling DNA microarrays [23] and massively parallel DNA
sequencing methods [9,10,24], with the latter predominating in
ongoing efforts. Both polyA+ and polyA2 RNAs are being
analyzed. Because subcellular compartmentalization of RNAs is
important in RNA processing and function, such as nuclear
retention of unspliced coding transcripts [25] or snoRNA activity
in the nucleolus [26], ENCODE is analyzing not only total whole
cell RNAs but also those concentrated in the nucleus and cytosol.
Long (.200 nt) and short RNAs (,200 nt) are being sequenced
from each subcellular compartment, providing catalogs of
potential miRNAs, snoRNA, promoter-associated short RNAs
(PASRs) [27], and other short cellular RNAs. Total RNA from
K562 and GM12878 cells has been mapped by hybridization to
high-density tiling arrays and sequenced to a depth of .500
million paired-end 76 bp reads under conditions where the strand
of the RNA transcript is determined, providing considerable depth
of transcript coverage (see below).
These analyses reveal that the human genome encodes a diverse
array of transcripts. For example, in the proto-oncogene TP53
locus, RNA-seq data indicate that, while TP53 transcripts are
accurately assigned to the minus strand, those for the oppositely
transcribed, adjacent gene WRAP53 emanate from the plus strand
(Figure 3). An independent transcript within the first intron of
TP53 is also observed in both GM12878 and K562 cells (Figure 3).
Additional transcript annotations include exonic regions and
splice junctions, transcription start sites (TSSs), transcript 39 ends,
spliced RNA length, locations of polyadenylation sites, and
locations with direct evidence of protein expression. TSSs and 39
ends of transcripts are being determined with two approaches,
Paired-End diTag (PET) [28] and Cap-Analysis of Gene
Expression (CAGE) [29–31] sequencing.
Table 1. Experimental assays used by the ENCODE Consortium.
Gene/Transcript Analysis
Region/Feature Method Group
Gene annotation GENCODE Wellcome Trust
PolyA+ coding regions RNA-seq; tiling DNA microarrays; PET CSHL; Stanford/Yale//Harvard; Caltech
Total RNA coding regions RNA-seq; tiling DNA microarrays; PET CSHL
Coding regions in subcellular RNA fractions
(e.g. nuclear, cytoplasmic)
PET CSHL
Small RNAs short RNA-seq CSHL
Transcription initiation (59-end) and
termination (3-end9) sites
CAGE; diTAGs RIKEN, GIS
Full-length RNAs RACE University of Geneva; University of Lausanne
Protein-bound RNA coding regions RIP; CLIP SUNY-Albany; CSHL
Transcription Factors/Chromatin
Elements/Regions Method(s) Group(s)
Transcription Factor Binding Sites
(TFBS)
ChIP-seq Stanford/Yale/UC-Davis/Harvard; HudsonAlpha/Caltech;
Duke/UT-Austin; UW; U. Chicago/Stanford
Chromatin structure (accessibility, etc.) DNaseI hypersensitivity; FAIRE UW; Duke; UNC
Chromatin modifications (H3K27ac,
H3K27me3, H3K36me3, etc.)
ChIP-seq Broad; UW
DNaseI footprints Digital genomic footprinting UW
Other Elements/Features
Feature Method(s) Group(s)
DNA methylation RRBS; Illumina Methyl27; Methyl-seq HudsonAlpha
Chromatin interactions 5C; CHIA-PET UMass; UW; GIS
Genotyping Illumina 1M Duo HudsonAlpha
doi:10.1371/journal.pbio.1001046.t001
Figure 2. Data available from the ENCODE Consortium. (A) A data matrix representing all ENCODE data types. Each row is a method and each
column is a cell line on which the method could be applied to generate data. Colored cells indicate that data have been generated for that method
on that cell line. The different colors represent data generated from different groups in the Consortium as indicated by the key at the bottom of the
figure. In some cases, more than one group has generated equivalent data; these cases are indicated by subdivision of the cell to accommodate
multiple colors. (B) Data generated by ChIP-seq are split into a second matrix where the cells now represent cell types (rows) split by the factor or
histone modification to which the antibody is raised (columns). The colors again represent the groups as indicated by the key. The upper left corner
of this matrix has been expanded immediately above the panel to better illustrate the data. All data were collected from the ENCODE public
download repository at http://hgdownload.cse.ucsc.edu/goldenPath/hg18/encodeDCC on September 1, 2010.
doi:10.1371/journal.pbio.1001046.g002
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Transcript annotations throughout the genome are further
corroborated by comparing tiling array data with deep sequencing
data and by the manual curation described above. Additionally,
selected compartment-specific RNA transcripts that cannot be
mapped to the current build of the human genome sequence have
been evaluated by 59/39 Rapid Amplification of cDNA Ends
(RACE) [32], followed by RT-PCR cloning and sequencing. To
assess putative protein products generated from novel RNA
transcripts and isoforms, proteins may be sequenced and
quantified by mass spectrometry and mapped back to their
encoding transcripts [33,34]. ENCODE has recently begun to
study proteins from distinct subcellular compartments of K562
and GM12878 cells by using this complementary approach.
Cis-Regulatory Regions
Cis-regulatory regions include diverse functional elements (e.g.,
promoters, enhancers, silencers, and insulators) that collectively
modulate the magnitude, timing, and cell-specificity of gene
expression [35]. The ENCODE Project is using multiple
approaches to identify cis-regulatory regions, including localizing
their characteristic chromatin signatures and identifying sites of
occupancy of sequence-specific transcription factors. These
approaches are being combined to create a comprehensive map
of human cis-regulatory regions.
Chromatin structure and modification. Human cis-
regulatory regions characteristically exhibit nuclease hyper-
sensitivity [36–39] and may show increased solubility after
chromatin fixation and fragmentation [40,41]. Additionally,
specific patterns of post-translational histone modifications [42,43]
have been connected with distinct classes of regions such as
promoters and enhancers [3,44–47] as well as regions subject to
programmed repression by Polycomb complexes [48,49] or other
mechanisms [46,50,51]. Chromatin accessibility and histone
modifications thus provide independent and complementary
annotations of human regulatory DNA, and massively parallel,
high-throughput DNA sequencing methods are being used by
ENCODE to map these features on a genome-wide scale (Figure 2
and Table 1).
DNaseI hypersensitive sites (DHSs) are being mapped by two
techniques: (i) capture of free DNA ends at in vivo DNaseI
cleavage sites with biotinylated adapters, followed by digestion
with a TypeIIS restriction enzyme to generate ,20 bp DNaseI
Figure 3. ENCODE gene and transcript annotations. The image shows selected ENCODE and other gene and transcript annotations in the
region of the human TP53 gene (region chr17:7,560,001–7,610,000 from the Human February 2009 (GRCh37/hg19) genome assembly). The annotated
isoforms of TP53 RNAs listed from the ENCODE Gene Annotations (GENCODE) are shown in the top tracks of the figure, along with annotation of the
neighboring WRAP53 gene. In black are two mRNA transcripts (U58658/AK097045) from GenBank. The bottom two tracks show the structure of the
TP53 region transcripts detected in nuclear polyadenylated poly A+ RNAs isolated from GM12878 and K562 cells. The RNA is characterized by RNA-
seq and the RNAs detected are displayed according to the strand of origin (i.e. + and 2). Signals are scaled and are present at each of the detected
p53 exons. Signals are also evident at the U58658 [120] and AK097045 [121] regions located in the first 10 kb intron of the p53 gene (D17S2179E). The
U58658/AK097045 transcripts are reported to be induced during differentiation of myeloid leukemia cells but are seen in both GM12878 and K562
cell lines. Finally the p53 isoform observed in K562 cells has a longer 39UTR region than the isoform seen in the GM12878 cell line.
doi:10.1371/journal.pbio.1001046.g003
Table 2. ENCODE cell types.
Cell Type Tier Description Source
GM12878 1 B-Lymphoblastoid cell line Coriell GM12878
K562 1 Chronic Myelogenous/Erythroleukemia cell line ATCC CCL-243
H1-hESC 1 Human Embryonic Stem Cells, line H1 Cellular Dynamics International
HepG2 2 Hepatoblastoma cell line ATCC HB-8065
HeLa-S3 2 Cervical carcinoma cell line ATCC CCL-2.2
HUVEC 2 Human Umbilical Vein Endothelial Cells Lonza CC-2517
Various (Tier 3) 3 Various cell lines, cultured primary cells, and primary tissues Various
doi:10.1371/journal.pbio.1001046.t002
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cleavage site tags [52,53] and (ii) direct sequencing of DNaseI
cleavage sites at the ends of small (,300 bp) DNA fragments
released by limiting treatment with DNaseI [54–56]. Chromatin
structure is also being profiled with the FAIRE technique
[40,57,58], in which chromatin from formaldehyde-crosslinked
cells is sonicated in a fashion similar to ChIP and then extracted
with phenol, followed by sequencing of soluble DNA fragments.
An expanding panel of histone modifications (Figure 2) is being
profiled by ChIP-seq [59–62]. In this method, chromatin from
crosslinked cells is immunoprecipitated with antibodies to
chromatin modifications (or other proteins of interest), the
associated DNA is recovered, and the ends are subjected to
massively parallel DNA sequencing. Control immunoprecipita-
tions with a control IgG antibody or ‘‘input’’ chromatin—
sonicated crosslinked chromatin that is not subjected to immune
enrichment—are also sequenced for each cell type. These provide
critical controls, as shearing of crosslinked chromatin may occur
preferentially within certain regulatory DNA regions, typically
promoters [41]. ENCODE chromatin data types are illustrated for
a typical locus in Figure 4, which depicts the patterns of chromatin
accessibility, DNaseI hypersensitive sites, and selected histone
modifications in GM12878 cells.
For each chromatin data type, the ‘‘raw signal’’ is presented as
the density of uniquely aligning sequence reads within 150 bp
sliding windows in the human genome. In addition, some data are
available as processed signal tracks in which filtering algorithms
have been applied to reduce experimental noise. A variety of
specialized statistical algorithms are applied to generate discrete
high-confidence genomic annotations, including DHSs, broader
regions of increased sensitivity to DNaseI, regions of enrichment
by FAIRE, and regions with significant levels of specific histone
modifications (see Tables 3 and S1). Notably, different histone
modifications exhibit characteristic genomic distributions that may
be either discrete (e.g., H3K4me3 over a promoter) or broad (e.g.,
H3K36me3 over an entire transcribed gene body). Because
statistical false discovery rate (FDR) thresholds are applied to
discrete annotations, the number of regions or elements identified
under each assay type depends upon the threshold chosen.
Optimal thresholds for an assay are typically determined by
comparison to an independent and standard assay method or
through reproducibility measurements (see below). Extensive
validation of the detection of DNaseI hypersensitive sites is being
performed independently with traditional Southern blotting, and
more than 6,000 Southern images covering 224 regions in .12
cell types are available through the UCSC browser.
Transcription factor and RNA polymerase occupancy.
Much of human gene regulation is determined by the binding of
transcriptional regulatory proteins to their cognate sequence
elements in cis-regulatory regions. ChIP-seq enables genome-scale
mapping of transcription factor (TF) occupancy patterns in vivo
[59,60,62] and is being extensively applied by ENCODE to create
an atlas of regulatory factor binding in diverse cell types. ChIP-seq
experiments rely on highly specific antibodies that are extensively
characterized by immunoblot analysis and other criteria according
Figure 4. ENCODE chromatin annotations in the HLA locus. Chromatin features in a human lymphoblastoid cell line, GM12878, are displayed
for a 114 kb region in the HLA locus. The top track shows the structures of the annotated isoforms of the HLA-DRB1, HLA-DQA1, and HLA-DQB1 genes
from the ENCODE Gene Annotations (GENCODE), revealing complex patterns of alternative splicing and several non-protein-coding transcripts
overlapping the protein-coding transcripts. The purple mark on the next line shows that a CpG in the promoter of the HLA-DQB1 gene is partially
methylated (assayed on the Illumina Methylation27 BeadArray platform). The densities of four histone modifications associated with transcriptionally
active loci are plotted next, along with the input control signal (generated by sequencing an aliquot of the sheared chromatin for which no
immunoprecipitation was performed). The last lines plot the accessibility of DNA in chromatin to nucleases (DNaseI) and reduced coverage by
nucleosomes (FAIRE); peaks on these lines are DNaseI hypersensitive sites. Note that the ENCODE Consortium generates DNaseI accessibility data by
two alternative protocols marked by * and #. The magenta track shows DNaseI sensitivity in a different cell line, NHEK, for comparison.
doi:10.1371/journal.pbio.1001046.g004
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to ENCODE experimental standards. High-quality antibodies are
currently available for only a fraction of human TFs, and identifying
suitable immunoreagents has been a major activity of ENCODE
TF mapping groups. Alternative technologies, such as epitope
tagging of TFs in their native genomic context using recom-
bineering [63,64], are also being explored.
ENCODE has applied ChIP-seq to create occupancy maps for
a variety of TFs, RNA polymerase 2 (RNA Pol2) including both
unphosphorylated (initiating) and phosphorylated (elongating)
forms, and RNA polymerase 3 (RNA Pol3). The localization
patterns of five transcription factors and RNA Pol2 in GM12878
lymphoblastoid cells are shown for a typical locus in Figure 5.
Sequence reads are processed as described above for DNaseI,
FAIRE, and histone modification experiments, including the
application of specialized peak-calling algorithms that use input
chromatin or control immunoprecipitation data to identify
potential false-positives introduced by sonication or sequencing
biases (Table 3). Although different peak-callers vary in perfor-
mance, the strongest peaks are generally identified by multiple
algorithms. Most of the sites identified by ChIP-seq are also
detected by traditional ChIP-qPCR [65] or are consistent with
sites reported in the literature. For example, 98% of 112 sites of
CTCF occupancy previously identified by using both ChIP-chip
and ChIP-qPCR [66] are also identified in ENCODE CTCF data.
Whereas the binding of sequence-specific TFs is typically highly
localized resulting in tight sequence tag peaks, signal from
antibodies that recognize the phosphorylated (elongating) form
of RNA Pol2 may detect occupancy over a wide region
encompassing both the site of transcription initiation as well as
the domain of elongation. Comparisons among ENCODE groups
have revealed that TF and RNA Pol2 occupancy maps generated
independently by different groups are highly consistent.
Additional Data Types
ENCODE is also generating additional data types to comple-
ment production projects and benchmark novel technologies. An
overview of these datasets is provided in Table 1.
DNA methylation. In vertebrate genomes, methylation at
position 5 of the cytosine in CpG dinucleotides is a heritable
‘‘epigenetic’’ mark that has been connected with both
transcriptional silencing and imprinting [67,68]. ENCODE is
applying several complementary approaches to measure DNA
methylation. All ENCODE cell types are being assayed using two
direct methods for measuring DNA methylation following sodium
bisulfite conversion, which enables quantitative analysis of
methylcytosines: interrogation of the methylation status of
27,000 CpGs with the Illumina Methyl27 assay [69–72] and
Reduced Representation Bisulfite Sequencing (RRBS) [73], which
couples MspI restriction enzyme digestion, size selection, bisulfite
treatment, and sequencing to interrogate the methylation status of
.1,000,000 CpGs largely concentrated within promoter regions
and CpG islands. Data from an indirect approach using a
methylation-sensitive restriction enzyme (Methyl-seq) [74] are also
available for a subset of cell types. These three approaches
measure DNA methylation in defined (though overlapping) subsets
of the human genome and provide quantitative determinations of
the fraction of CpG methylation at each site.
DNaseI footprints. DNaseI footprinting [75] enables
visualization of regulatory factor occupancy on DNA in vivo at
nucleotide resolution and has been widely applied to delineate the
fine structure of cis-regulatory regions [76]. Deep sampling of
highly enriched libraries of DNaseI-released fragments (see above)
enables digital quantification of per nucleotide DNaseI cleavage,
which in turn enables resolution of DNaseI footprints on a large
scale [55,77,78]. Digital genomic footprinting is being applied on a
large scale within ENCODE to identify millions of DNaseI
footprints across .12 cell types, many of which localize the
specific cognate regulatory motifs for factors profiled by ChIP-seq.
Sequence and structural variation. Genotypic and
structural variations within all ENCODE cell types are being
interrogated at ,1 million positions distributed approximately
every 1.5 kb along the human genome, providing a finely grained
map of allelic variation and sequence copy number gains and
losses. Genotyping data are generated with the Illumina Infinium
Table 3. Analysis tools applied by the ENCODE Consortium.
Class of Software Description of Task Examplesa
Short read alignment Computationally efficient alignment of short reads to the genome sequence Bowtie, BWA, Maq, TopHat, GEM, STAR
Peak calling Converting tag density to defined regions that show statistical
properties consistent with binding activity
SPP, PeakSeq, Fseq, MACS, HotSpot
RNA processing Processing RNA reads into exons and transcripts, with consideration
of alternative splicing
Cufflinks, ERANGE, Fluxcapacitor
Integrative peak calling and
classification
Jointly considering multiple assay signals to both define the location
and character of different genomic regions
ChromHMM, Segway
Statistical tools for specific
genomic tasks
Statistical methods developed for replicate-based thresholding,
genome-wide-based overlap, and genome-based aggregation
IDR, GSC, ACT
Motif finding tools Discovering the presence of sequence motifs in enriched peaks MEME, Weeder
Data analysis frameworks General frameworks to allow manipulation, comparison,
and statistical analysis
R, Bioconductor, MatLab, Galaxy, DART,
Genometools
Assign TFBS peaks to genes Match TFBS to genes they are likely to regulate GREAT
Compare TF binding and
gene expression
Compare binding and expression; compare expressed versus
nonexpressed genes
GenPattern, GSEA, Dchip
Conservation Evaluates conservation of sequences across a range of species phastCons, GERP, SCONE
Gene Ontology Analysis Determine types of genes enriched for a given dataset GO miner, BINGO, AmiGO
Network analysis Examine relationships between genes Cytoscape
aFor full listings and references, see Table S1.
doi:10.1371/journal.pbio.1001046.t003
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Figure 5. Occupancy of transcription factors and RNA polymerase 2 on human chromosome 6p as determined by ChIP-seq. The
upper portion shows the ChIP-seq signal of five sequence-specific transcription factors and RNA Pol2 throughout the 58.5 Mb of the short arm of
human chromosome 6 of the human lymphoblastoid cell line GM12878. Input control signal is shown below the RNA Pol2 data. At this level of
resolution, the sites of strongest signal appear as vertical spikes in blue next to the name of each experiment (‘‘BATF,’’ ‘‘EBF,’’ etc.). More detail can be
seen in the bottom right portion, where a 116 kb segment of the HLA region is expanded; here, individual sites of occupancy can be seen mapping
to specific regions of the three HLA genes shown at the bottom, with asterisks indicating binding sites called by peak calling software. Finally, the
lower left region shows a 3,500 bp region around two tandem histone genes, with RNA Pol2 occupancy at both promoters and two of the five
transcription factors, BATF and cFos, occupying sites nearby. Selected annotations from the ENCODE Gene Annotations are shown in each case.
doi:10.1371/journal.pbio.1001046.g005
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platform [79], and the results are reported as genotypes and as
intensity value ratios for each allele. The genotype and sequence
data from GM12878 generated by the 1,000 Genomes Project are
being integrated with sequence data from ENCODE chromatin,
transcription, TF occupancy, DNA methylation, and other assays
to facilitate recognition of functional allelic variation, a significant
contributor to phenotypic variability in gene expression [80,81].
The data also permit determination of the sequence copy number
gains and losses found in every human genome [82–84], which are
particularly prevalent in cell lines of malignant origin.
Long-range Chromatin interactions. Because cis-regulatory
elements such as enhancers can control genes from distances of tens
to hundreds of kb through looping interactions [85], a major
challenge presented by ENCODE data is to connect distal
regulatory elements with their cognate promoter(s). To map this
connectivity, the Consortium is applying the 5C method [86], an
enhanced version of Chromosome Conformation Capture (3C)
[87], to selected cell lines. 5C has been applied comprehensively to
the ENCODE pilot regions as well as to map the interactions
between distal DNaseI hypersensitive sites and transcriptional start
sites across chromosome 21 and selected domains throughout the
genome. Special interfaces have been developed to visualize these 3-
dimensional genomic data and are publicly available at http://
my5C.umassmed.edu [88].
Protein:RNA interactions. RNA-binding proteins play a
major role in regulating gene expression through control of
mRNA translation, stability, and/or localization. Occupancy of
RNA-binding proteins (RBPs) on RNA can be determined by
using immunoprecipitation-based approaches (RIP-chip and RIP-
seq) [89–92] analogous to those used for measuring TF occupancy.
To generate maps of RBP:RNA associations and binding sites, a
combination of RIP-chip and RIP-seq are being used. These
approaches are currently targeting 4–6 RBPs in five human cell
types (K562, GM12878, H1 ES, HeLa, and HepG2). RBP
associations with non-coding RNA and with mRNA are also being
explored.
Identification of functional elements with integrative
analysis and fine-scale assays of biochemical
elements. ChIP-seq of TFs and chromatin modifications may
identify genomic regions bound by transcription factors in living cells
but do not reveal which segments bound by a given TF are
functionally important for transcription. By applying integrative
approaches that incorporate histone modifications typical of
enhancers (e.g., histone H3, Lysine 4 monomethylation), promoters
(e.g., histone H3, Lysine 4 trimethylation), and silencers (e.g., Histone
H3, Lysine 27, and Lysine 9 trimethylation), ENCODE is
categorizing putative functional elements and testing a subset for
activities in the context of transient transfection/reporter gene assays
[93–97]. To further pinpoint the biological activities associated with
specific regions of TF binding and chromatin modification within
promoters, hundreds of TF binding sites have been mutagenized, and
the mutant promoters are being assayed for effects on reporter gene
transcription by transient transfection assays. This approach is
enabling identification of specific TF binding sites that lead to
activation and others associated with transcriptional repression.
Proteomics. To assess putative protein products generated
from novel RNA transcripts and isoforms, proteins are sequenced
and quantified by mass spectrometry and mapped back to their
encoding transcripts [33,34,98]. ENCODE has recently begun to
study proteins from distinct subcellular compartments of K562
and GM12878 with this complementary approach.
Evolutionary conservation. Evolutionary conservation is an
important indicator of biological function. ENCODE is app-
roaching evolutionary analysis from two directions. Functional
properties are being assigned to conserved sequence elements
identified through multi-species alignments, and conversely, the
evolutionary histories of biochemically defined elements are being
deduced. Multiple alignments of the genomes of 33 mammalian
species have been constructed by using the Enredo, Pecan, Ortheus
approach (EPO) [99,100], and complementary multiple alignments
are available through the UCSC browser (UCSC Lastz/ChainNet/
Multiz). These alignments enable measurement of evolutionary
constraint at single-nucleotide resolution using GERP [101],
SCONE [102], PhyloP [103], and other algorithms. In addition,
conservation of DNA secondary structure based on hydroxyl
radical cleavage patterns is being analyzed with the Chai algorithm
[7].
Data Production Standards and Assessment of Data
Quality
With the aim of ensuring quality and consistency, ENCODE
has defined standards for collecting and processing each data
type. These standards encompass all major experimental
components, including cell growth conditions, antibody charac-
terization, requirements for controls and biological replicates, and
assessment of reproducibility. Standard formats for data submis-
sion are used that capture all relevant data parameters and
experimental conditions, and these are available at the public
ENCODE portal (http://genome.ucsc.edu/ENCODE/dataStan
dards.html). All ENCODE data are reviewed by a dedicated
quality assurance team at the Data Coordination Center before
release to the public. Experiments are considered to be verified
when two highly concordant biological replicates have been
obtained with the same experimental technique. In addition, a
key quality goal of ENCODE is to provide validation at multiple
levels, which can be further buttressed by cross-correlation
between disparate data types. For example, we routinely perform
parallel analysis of the same biological samples with alternate
detection technologies (for example, ChIP-seq versus ChIP-chip
or ChIP-qPCR). We have also compared our genome-wide
results to ‘‘gold-standard’’ data from individual locus studies, such
as DNase-seq versus independently performed conventional
(Southern-based) DNaseI hypersensitivity studies. Cross-correla-
tion of independent but related ENCODE data types with one
another, such as DNaseI hypersensitivity, FAIRE, transcription
factor occupancy, and histone modification patterns, can provide
added confidence in the identification of specific DNA elements.
Similarly, cross-correlation between long RNA-seq, CAGE, and
TAF1 ChIP-seq data can strengthen confidence in a candidate
location for transcription initiation. Finally, ENCODE is
performing pilot tests for the biological activity of DNA elements
to the predictive potential of various ENCODE biochemical
signatures for certain biological functions. Examples include
transfection assays in cultured human cells and injection assays in
fish embryos to test for enhancer, silencer, or insulator activities
in DNA elements identified by binding of specific groups of TFs
or the presence of DNaseI hypersensitive sites or certain
chromatin marks. Ultimately, defining the full biological role of
a DNA element in its native chromosomal location and
organismic context is the greatest challenge. ENCODE is
beginning to approach this by integrating its data with results
from other studies of in situ knockouts and/or knockdowns, or
the identification of specific naturally occurring single base
mutations and small deletions associated with changes in gene
expression. However, we expect that deep insights into the
function of most elements will ultimately come from the
community of biologists who will build on ENCODE data or
use them to complement their own experiments.
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Current Scope and Completeness of ENCODE Data
A catalog of ENCODE datasets is available at http://
encodeproject.org. These data provide evidence that ,1 Gigabase
(Gb; 32%) of the human genome sequence is represented in
steady-state, predominantly processed RNA populations. We have
also delineated more than 2 million potential regulatory DNA
regions through chromatin and TF mapping studies.
The assessment of the completeness of detection of any given
element is challenging. To analyze the detection of transcripts in a
single experiment, we have sequenced to substantial depth and
used a sampling approach to estimate the number of reads needed
to approach complete sampling of the RNA population (Figure 6A)
[104]. For example, analyzing RNA transcripts with about 80
million mapped reads yields robust quantification of more than
80% of the lowest abundance class of genes (2–19 reads per
kilobase per million mapped tags, RPKM) [24]. Measuring RNAs
across multiple cell types, we find that, after the analysis of seven
cell lines, 68% of the GENCODE transcripts can be detected with
RPKM .1.
In the case of regulatory DNA, we have analyzed the detection
of regulatory DNA by using three approaches: 1) the saturation of
occupancy site discovery for a single transcription factor within a
single cell type as a function of sequencing read depth, 2) the
incremental discovery of DNaseI hypersensitive sites or the
occupancy sites for a single TF across multiple cell types, and 3)
the incremental rate of collective TF occupancy site discovery for
all TFs across multiple cell types.
For detecting TF binding sites by ChIP-seq, we have found that
the number of significant binding sites increases as a function of
sequencing depth and that this number varies widely by
transcription factor. For example, as shown in Figure 6B, 90%
of detectable sites for the transcription factor GABP can be
identified by using the MACS peak calling program at a depth of
24 million reads, whereas only 55% of detectable RNA Pol2 sites
are identified at this depth when an antibody that recognizes both
initiating and elongating forms of the enzyme is used. Even at 50
million reads, the number of sites is not saturated for RNA Pol2
with this antibody. It is important to note that determinations of
saturation may vary with the use of different antibodies and
laboratory protocols. For instance, a different RNA Pol2 antibody
that recognizes unphosphorylated, non-elongating RNA Pol2
bound only at promoters requires fewer reads to reach saturation
[105]. For practical purposes, ENCODE currently uses a
minimum sequencing depth of 20 M uniquely mapped reads for
sequence-specific transcription factors. For data generated prior to
June 1, 2010, this figure was 12 M.
To assess the incremental discovery of regulatory DNA across
different cell types, it was necessary to account for the non-uniform
correlation between cell lines and assays (see Figure 6C legend for
details). We therefore examined all possible orderings of either cell
types or assays and calculated the distribution of elements
discovered as the number of cell types or assays increases,
presented as saturation distribution plots (Figure 6C and 6D,
respectively). For DNase hypersensitive sites, we observe a steady
increase in the mean number of sites discovered as additional cell
types are tested up to and including the 62 different cell types
examined to date, indicating that new elements continue to be
identified at a relatively high rate as additional cell types are
sampled (Figure 6C). Analysis of CTCF sites across 28 cell types
using this approach shows similar behavior. Analysis of binding
sites for 42 TFs in the cell line with most data (K562) also shows
that saturation of the binding sites for these factors has not yet
been achieved. These results indicate that additional cell lines need
to be analyzed for DNaseI and many transcription factors, and
that many more transcription factors need to be analyzed within
single cell types to capture all the regulatory information for a
given factor across the genome. The implications of these trends
for defining the extent of regulatory DNA within the human
genome sequence is as yet unclear.
III. Accessing ENCODE Data
ENCODE Data Release and Use Policy
The ENCODE Data Release and Use Policy is described
at http://www.encodeproject.org/ENCODE/terms.html. Briefly,
ENCODE data are released for viewing in a publicly accessible
browser (initially at http://genome-preview.ucsc.edu/ENCODE
and, after additional quality checks, at http://encodeproject.org).
The data are available for download and pre-publication analysis
of any kind, as soon as they are verified (i.e., shown to be
reproducible). However, consistent with the principles stated in the
Toronto Genomic Data Use Agreement [106], the ENCODE
Consortium data producers request that they have the first
publication on genome-wide analyses of ENCODE data, within a
9-month timeline from its submission. The timeline for each
dataset is clearly displayed in the information section for each
dataset. This parallels policies of other large consortia, such as the
HapMap Project (http://www.hapmap.org), that attempt to
balance the goal of rapid data release with the ability of data
producers to publish initial analyses of their work. Once a
producer has published a dataset during this 9-month period,
anyone may publish freely on the data. The embargo applies only
to global analysis, and the ENCODE Consortium expects and
encourages immediate use and publication of information at one
or a few loci, without any consultation or permission. For such
uses, identifying ENCODE as the source of the data by citing this
article is requested.
Public Repositories of ENCODE Data
After curation and review at the Data Coordination Center, all
processed ENCODE data are publicly released to the UCSC
Genome Browser database (http://genome.ucsc.edu). Accession-
ing of ENCODE data at the NCBI Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/info/ENCODE.html)
is underway. Primary DNA sequence reads are stored at UCSC
and the NCBI Sequence Read Archive (SRA; http://www.ncbi.
nlm.nih.gov/Traces/sra/sra.cgi?) and will also be retrievable via
GEO. Primary data derived from DNA microarrays (for example,
for gene expression) are deposited directly to GEO. The processed
data are also formatted for viewing in the UCSC browser.
Metadata, including information on antibodies, cell culture
conditions, and other experimental parameters, are deposited into
the UCSC database, as are results of validation experiments. Easy
retrieval of ENCODE data to a user’s desktop is facilitated by the
UCSC Table Browser tool (http://genome.ucsc.edu/cgi-bin/
hgTables?org=human), which does not require programming
skills. Computationally sophisticated users may gain direct access
to data through application programming interfaces (APIs) at both
the UCSC browser and NCBI and by downloading files from
http://genome.ucsc.edu/ENCODE/downloads.html.
An overview of ENCODE data types and the location of the
data repository for each type is presented in Table 4.
IV. Working with ENCODE Data
Using ENCODE Data in the UCSC Browser
Many users will want to view and interpret the ENCODE data
for particular genes of interest. At the online ENCODE portal
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Figure 6. Incremental discovery of transcribed elements and regulatory DNA. (A) Robustness of gene expression quantification relative to
sequencing depth. PolyA-selected RNA from H1 human embryonic stem cells was sequenced to 214 million mapped reads. The number of reads
(indicated on the x-axis) was sampled from the total, and gene expression (in FPKM) was calculated and compared to the gene expression values
resulting from all the reads (final values). Gene expression levels were split into four abundance classes and the fraction of genes in each class with
RPKM values within 10% of the final values was calculated. At ,80 million mapped reads, more than 80% of the low abundance class of genes is
robustly quantified according to this measure (horizontal dotted line). Abundances for the classes in RPKM are given in the inset box. (B) Effect of
number of reads on fractions of peaks called in ChIP-seq. ChIP-seq experiments for three sequence-specific transcription factors were sequenced to a
depth of 50 million aligned reads. To evaluate the effect of read depth on the number of binding sites identified, peaks were called with the MACS
algorithm at various read depths, and the fraction of the total number of peaks that were identified at each read depth are shown. For sequence-
specific transcription factors that have strong signal with ChIP-seq, such as GABP, approximately 24 million reads (dashed vertical line) are sufficient
to capture 90% of the binding sites. However, for more general sequence-specific factors (e.g., OCT2), additional sequencing continues to yield
additional binding site information. RNA Pol2, which interacts with DNA broadly across genes, maintains a nearly linear gain in binding information
through 50 million aligned reads. (C) Saturation analysis of ENCODE DNaseI hypersensitivity data with increasing numbers of cell lines. The plot shows
the extent of saturation of DNaseI hypersensitivity sites (DHSs) discovered as increasing numbers of cell lines are studied. The plot is generated from
the ENCODE DNaseI elements defined at the end of January 2010 (from http://hgdownload.cse.ucsc.edu/goldenPath/hg18/encodeDCC) as follows.
We first define a set of DHSs from the overlap of all DHS data across all cell lines. Where overlapping elements are identified in two or more cell lines,
these are determined to represent the same element and fused up to a maximum size of 5 kb. Elements above this limit are split and counted as
distinct. We then calculate the subset of these elements represented by each single cell line experiment. The distribution of element counts for each
single cell line is plotted as a box plot with the median at position 1 on the x-axis. We next calculate the element contributions of all possible pairs of
cell line experiments and plot this distribution at position 2. We continue to do this for all incremental steps up to and including all cell lines (which is
A User’s Guide to ENCODE
PLoS Biology | www.plosbiology.org 12 April 2011 | Volume 9 | Issue 4 | e1001046
(http://encodeproject.org), users should follow a ‘‘Genome
Browser’’ link to visualize the data in the context of other genome
annotations. Currently, it is useful for users to examine both the
hg18 and the hg19 genome browsers. The hg18 has the ENCODE
Integrated Regulation Track on by default, which shows a huge
amount of data in a small amount of space. The hg19 browser has
newer datasets, and more ENCODE data than are available on
hg18. Work is in progress to remap the older hg18 datasets to hg19
and generate integrated ENCODE tracks. On either browser,
additional ENCODE tracks are marked by a double helix logo in
the browser track groups for genes, transcripts, and regulatory
features. Users can turn tracks on or off to develop the views most
useful to them (Figure 7). To aid users in navigating the rich
variety of data tracks, the ENCODE portal also provides a
detailed online tutorial that covers data display, data download,
and analysis functions available through the browser. Examples
applying ENCODE data at individual loci to specific biological or
medical issues are a good starting point for exploration and use of
the data. Thus, we also provide a collection of examples at the
‘‘session gallery’’ at the ENCODE portal. Users are encouraged to
submit additional examples; we anticipate that this community-
based sharing of insights will accelerate the use and impact of the
ENCODE data.
An Illustrative Example
Numerous genome-wide association studies (GWAS) that link
human genome sequence variants with the risk of disease or with
common quantitative phenotypes have now become available.
However, in most cases, the molecular consequences of disease- or
trait-associated variants for human physiology are not understood
[107]. In more than 400 studies compiled in the GWAS catalog
[108], only a small minority of the trait/disease-associated SNPs
(TASs) occur in protein-coding regions; the large majority (89%)
are in noncoding regions. We therefore expect that the
accumulating functional annotation of the genome by ENCODE
will contribute substantially to functional interpretation of these
TASs.
For example, common variants within a ,1 Mb region
upstream of the c-Myc proto-oncogene at 8q24 have been
associated with cancers of the colon, prostate, and breast
(Figure 8A) [109–111]. ENCODE data on transcripts, histone
modifications, DNase hypersensitive sites, and TF occupancy show
strong, localized signals in the vicinity of major cancer-associated
SNPs. One variant (rs698327) lies within a DNase hypersensitive
site that is bound by several TFs and the enhancer-associated
protein p300 and contains histone modification patterns typical of
enhancers (high H3K4me1, low H3K4me3; Figure 8B). Recent
studies have shown enhancer activity and allele-specific binding of
TCF7L2 at this site [112], with the risk allele showing greater
binding and activity [113,114]. Moreover, this element appears to
contact the downstream c-Myc gene in vivo, compatible with
enhancer function [114,115]. Similarly, several regions predicted
via ENCODE data to be involved in gene regulation are close to
SNPs in the BCL11A gene associated with persistent expression of
fetal hemoglobin (Figure S2). These examples show that the simple
overlay of ENCODE data with candidate non-coding risk-
associated variants may readily identify specific genomic elements
as leading candidates for investigation as probable effectors of
phenotypic effects via alterations in gene expression or other
genomic regulatory processes. Importantly, even data from cell
types not directly associated with the phenotype of interest may be
of considerable value for hypothesis generation. It is reasonable to
expect that application of current and future ENCODE data will
provide useful information concerning the mechanism(s) whereby
genomic variation influences susceptibility to disease, which then
can then be tested experimentally.
Limitations of ENCODE Annotations
All ENCODE datasets to date are from populations of cells.
Therefore, the resulting data integrate over the entire cell
population, which may be physiologically and genetically
inhomogeneous. Thus, the source cell cultures in the ENCODE
experiments are not typically synchronized with respect to the cell
cycle and, as with all such samples, local micro-environments in
culture may also vary, leading to physiological differences in cell
state within each culture. In addition, one Tier 1 cell line (K562)
and two Tier 2 cell lines (HepG2 and HeLa) are known to have
abnormal genomes and karyotypes, with genome instability.
Finally, some future Tier 3 tissue samples or primary cultures
may be inherently heterogeneous in cell type composition.
Averaging over heterogeneity in physiology and/or genotype
produces an amalgamation of the contributing patterns of gene
Table 4. Overview of ENCODE data types.
Data Description Location
Metadata Experimental parameters (e.g., growth conditions, antibody characterization) UCSC, GEO
Primary data images CCD camera images from sequencers or microarrays Not archived
Sequence reads/microarray signal Minimally processed experimental data; reads and quality information; probe
locations and intensities
UCSC, GEO, SRA
Aligned sequence reads Sequence reads and genomic positions UCSC, GEO
Genomic signal Sequence tag density (sliding window); cumulative base coverage or density by
sequencing or read pseudo-extension; microarray probe intensity
UCSC, GEO
Enriched region calls/scores/p or q values Putative binding or transcribed regions UCSC, GEO
doi:10.1371/journal.pbio.1001046.t004
by definition only a single data point). (D) Saturation of TF ChIP-seq elements in K562 cells. This plot illustrates the saturation of elements identified
by TF ChIP-seq as additional factors are analyzed within the same cell line. The plot is generated by the equivalent approach as described in (C),
except the data are now the set of all elements defined by ChIP-seq analysis of K562 cells with 42 different transcription factors. The data were from
the January 2010 data freeze from http://hgdownload.cse.ucsc.edu/goldenPath/hg18/encodeDCC. For consistency, the peak calls from all ChIP-seq
data were generated by a uniform processing pipeline with the Peakseq peak caller and IDR replicate reconciliation.
doi:10.1371/journal.pbio.1001046.g006
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Figure 7. Accessing ENCODE data at the UCSC Portal. Data and results for the ENCODE Project are accessible at the UCSC portal (http://
genome.ucsc.edu/ENCODE). ‘‘Signal tracks’’ for the different datasets are selected and displayed in the genome browser to generate images such as
those shown in Figures 3–4. The datasets are available from the Track Settings page; an example is shown that illustrates some of the key controls. A
dataset is selected and the Signal display plots the values of an assay for a given feature more or less continuously along a chromosome. The height,
range for the y-axis, windowing function, and many other aspects of the graph are controlled in the Signal Configuration window, accessed by
clicking on ‘‘Signal’’ (red oval #1). ENCODE data are commonly generated on multiple cell lines; information about each can be accessed by clicking
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expression, factor occupancy, and chromatin status that must be
considered when using the data. Future improvements in genome-
wide methodology that allow the use of much smaller amounts of
primary samples, or follow-up experiments in single cells when
possible, may allow us to overcome many of these caveats.
The use of DNA sequencing to annotate functional genomic
features is constrained by the ability to place short sequence reads
accurately within the human genome sequence. Most ENCODE
data types currently represented in the UCSC browser use only
those sequence reads that map uniquely to the genome. Thus,
centromeric and telomeric segments (collectively ,15% of the
genome and enriched in recent transposon insertions and
segmental duplications) as well as sequences not present in the
current genome sequence build [116] are not subject to reliable
annotation by our current techniques. However, such information
can be gleaned through mining of the publicly available raw
sequence read datasets generated by ENCODE.
It is useful to recognize that the confidence with which different
classes of ENCODE elements can be related to a candidate
function varies. For example, ENCODE can identify with high
confidence new internal exons of protein-coding genes, based on
RNA-seq data for long polyA+ RNA. Other features, such as
candidate promoters, can be identified with less, yet still good,
confidence by combining data from RNA-seq, CAGE-tags, and
RNA polymerase 2 (RNA Pol2) and TAF1 occupancy. Still other
ENCODE biochemical signatures come with much lower
confidence about function, such as a candidate transcriptional
enhancer supported by ChIP-seq evidence for binding of a single
transcription factor.
Identification of genomic regions enriched by ENCODE
biochemical assays relies on the application of statistical analyses
and the selection of threshold significance levels, which may vary
between the algorithms used for particular data types. According-
ly, discrete annotations, such as TF occupancy or DNaseI
hypersensitive sites, should be considered in the context of
reported p values, q values, or false discovery rates, which are
conservative in many cases. For data types that lack focal
enrichment, such as certain histone modifications and many
RNA Pol2-bound regions, broad segments of significant enrich-
ment have been delineated that encompass considerable quanti-
tative variation in the signal strength along the genome.
V. ENCODE Data Analysis
Development and implementation of algorithms and pipelines
for processing and analyzing data has been a major activity of the
ENCODE Project. Because massively parallel DNA sequencing
has been the main type of data generated by the Consortium,
much of the algorithmic development and data analysis to date has
been concerned with issues related to producing and interpreting
such data. Software packages and algorithms commonly used in
the ENCODE Consortium are summarized in Tables 3 and S1.
In general, the analysis of sequencing-based measurements of
functional or biochemical genomic parameters proceeds through
three major phases. In the first phase, the short sequences that are
the output of the experimental method are aligned to the reference
genome. Algorithm development for efficient and accurate
alignment of short read sequences to the human genome is a
rapidly developing field, and ENCODE groups employ a variety
of the state-of-the-art software (see Tables 3 and S1). In the second
phase, the initial sequence mapping is processed to identify
significantly enriched regions from the read density. For ChIP-seq
(TFs and histone modification), DNase-seq or FAIRE-seq, both
highly localized peaks or broader enriched regions may be
identified. Within the ENCODE Consortium, each data produc-
tion group provides lists of enriched regions or elements within
their own data, which are available through the ENCODE portal.
It should be noted that, for most data types, the majority of
enriched regions show relatively weak absolute signal, necessitating
the application of conservative statistical thresholds. For some
data, such as those derived from sampling RNA species (e.g.,
RNA-seq), additional algorithms and processing are used to
handle transcript structures and the recognition of splicing events.
The final stage of analysis involves integrating the identified
regions of enriched signal with each other and with other data
types. An important prerequisite to data integration is the
availability of uniformly processed datasets. Therefore, in addition
to the processing pipelines developed by individual production
groups, ENCODE has devoted considerable effort toward
establishing robust uniform processing for phases 1 and 2 to
enable integration. For signal comparison, specific consideration
has been given to deriving a normalized view of the sequence read
density of each experiment. In the case of ChIP-seq for TFs, this
process includes in silico extension of the sequence alignment to
reflect the experimentally determined average lengths of the input
DNA molecules that are sampled by the short sequence tag,
compensation for repetitive sequences that may lead to alignment
with multiple genomic locations, and consideration of the read
density of the relevant control or input chromatin experiment.
ENCODE has adopted a uniform standardized peak-calling
approach for transcription factor ChIP-seq, including a robust
and conservative replicate reconciliation statistic (Irreproducible
Discovery Rate, IDR [117], to yield comparable consensus peak
calls. As the project continues, we expect further standardizations
to be developed.
There are many different ways to analyze and integrate large,
diverse datasets. Some of the basic approaches include assigning
features to existing annotations (e.g., assigning transcribed regions
to annotated genes or Pol2-binding peaks to likely genes),
discovery of correlations among features, and identification of
particular gene classes (e.g., Gene Ontology categories) preferen-
tially highlighted by a given annotation. Many software tools exist
in the community for these purposes, including some developed
within the ENCODE Project, such as the Genome Structure
Correction statistic for assessing overlap significance [3]. Software
tools used for integration by ENCODE are summarized in
Tables 3 and S1.
VI. Future Plans and Challenges
Data Production Plans
The challenge of achieving complete coverage of all functional
elements in the human genome is substantial. The adult human
body contains several hundred distinct cell types, each of which
on the name of the cell line or antibody (e.g., HepG2, red oval #2). Many ENCODE tracks are actually composites of multiple subtracks; these can be
turned on and off by using the boxes in the central matrix or in the subtrack list below. Subtracks can be reordered individually by using drag and
drop in the browser image or the Track Settings page, or in logical groups by using the ‘‘Cell/Antibody/Views’’ (red oval #4) ordering controls.
Additional information about the feature and the assay, such as the antibody used, can be obtained by clicking on the name of the feature. Some
restrictions to the use of ENCODE data apply for a 9-month period after deposit of the data; the end of that 9-month period is given by the
‘‘Restricted Until’’ date. Full data can be downloaded by clicking on the ‘‘Downloads’’ link (red oval #7).
doi:10.1371/journal.pbio.1001046.g007
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Figure 8. ENCODE data indicate non-coding regions in the human chromosome 8q24 loci associated with cancer. (A) A 1 Mb region
includingMYC and a gene desert upstream shows the linkage disequilibrium blocks and positions of SNPs associated with breast and prostate cancer,
with both a custom track based on [121] and the resident track from the GWAS catalog. ENCODE tracks include GENCODE gene annotations, results
of mapping RNAs to high-density Affymetrix tiling arrays (cytoplasmic and nuclear polyA+ RNA), mapping of histone modifications (H3K4me3 and
H3K27Ac), DNaseI hypersensitive sites in liver and colon carcinoma cell lines (HepG2 and Caco-2), and occupancy by the transcription factor TCF7L2 in
HCT116 cells. (B) Expanded view of a 9 kb region containing the cancer-associated SNP rs6983267 (shown on the top line). In addition to the histone
modifications, DNaseI hypersensitive sites and factor occupancy described in (A), the ENCODE tracks also show occupancy by the coactivator p300
and the transcription factors RXRA, CEBPB, and HNF4A. Except as otherwise noted in brackets, the ENCODE data shown here are from the liver
carcinoma cell line HepG2.
doi:10.1371/journal.pbio.1001046.g008
A User’s Guide to ENCODE
PLoS Biology | www.plosbiology.org 16 April 2011 | Volume 9 | Issue 4 | e1001046
expresses a unique subset of the ,1,500 TFs encoded in the
human genome [118]. Furthermore, the brain alone contains
thousands of types of neurons that are likely to express not only
different sets of TFs but also a larger variety of non-coding RNAs
[119]. In addition, each cell type may exhibit a diverse array of
responses to exogenous stimuli such as environmental conditions
or chemical agents. Broad areas of fundamental chromosome
function, such as meiosis and recombination, remain unexplored.
Furthermore, ENCODE has focused chiefly on definitive cells and
cell lines, bypassing the substantial complexity of development and
differentiation. A truly comprehensive atlas of human functional
elements is not practical with current technologies, motivating our
focus on performing the available assays in a range of cell types
that will provide substantial near-term utility. ENCODE is
currently developing a strategy for addressing this cellular space
in a timely manner that maximizes the value to the scientific
community. Feedback from the user community will be a critical
component of this process.
Integrating ENCODE with Other Projects and the
Scientific Community
To understand better and functionally annotate the human
genome, ENCODE is making efforts to analyze and integrate data
within the project and with other large-scale projects. These efforts
include 1) defining promoter and enhancer regions by combining
transcript mapping and biochemical marks, 2) delineating distinct
classes of regions within the genomic landscape by their specific
combinations of biochemical and functional characteristics, and 3)
defining transcription factor co-associations and regulatory
networks. These efforts aim to extend our understanding of the
functions of the different biochemical elements in gene regulation
and gene expression.
One of the major motivations for the ENCODE Project has
been to aid in the interpretation of human genome variation that is
associated with disease or quantitative phenotypes. The Consor-
tium is therefore working to combine ENCODE data with those
from other large-scale studies, including the 1,000 Genomes
Project, to study, for example, how SNPs and structural variation
may affect transcript, regulatory, and DNA methylation data. We
foresee a time in the near future when the biochemical features
defined by ENCODE are routinely combined with GWAS and
other sequence variation–driven studies of human phenotypes.
Analogously, the systematic profiling of epigenomic features across
ex vivo tissues and stem cells currently being undertaken by the
NIH Roadmap Epigenomics program will provide synergistic data
and the opportunity to observe the state and behavior of
ENCODE-identified elements in human tissues representing
healthy and disease states.
These are but a few of many applications of the ENCODE data.
Investigators focused on one or a few genes should find many new
insights within the ENCODE data. Indeed, these investigators are
in the best position to infer potential functions and mechanisms
from the ENCODE data—ones that will also lead to testable
hypotheses. Thus, we expect that the work of many investigators
will be enhanced by these data and that their results will in turn
inform the development of the project going forward.
Finally, we also expect that comprehensive paradigms for gene
regulation will begin to emerge from our work and similar work
from many laboratories. Deciphering the ‘‘regulatory code’’ within
the genome and its associated epigenetic signals is a grand and
complex challenge. The data contributed by ENCODE in
conjunction with complementary efforts will be foundational to
this effort, but equally important will be novel methods for
genome-wide analysis, model building, and hypothesis testing. We
therefore expect the ENCODE Project to be a major contributor
not only of data but also novel technologies for deciphering the
human genome and those of other organisms.
Supporting Information
Figure S1 The Organization of the ENCODE Consortium. The
geographical distribution of the members of the ENCODE
Consortium, with pin colors indicating the group roles as detailed
in the text below.
(TIF)
Figure S2 Quantitative trait example (BCL11A). Candidates for
gene regulatory features in the vicinity of SNPs at the BCL11A
locus associated with fetal hemoglobin levels. SNPs associated with
fetal hemoglobin levels are marked in red on the top line; those not
associated are marked in blue. The phenotype-associated SNPs are
close to an antisense transcript (AC009970.1, light orange), shown
in the ENCODE gene annotations. This antisense transcript is
within a region (boxed in red) with elevated levels of H3K
4me1 and DNase hypersensitive sites. The phenotype-associated
region is flanked by two regions (boxed in blue) with multiple
strong biochemical signals associated with transcriptional regula-
tion, including transcription factor occupancy. The data are from
the lymphoblastoid cell line GM12878, as BCL11A is expressed in
this cell line (RNA-seq track) but not in K562 (unpublished data).
(TIF)
Table S1 This supplemental table contains additional details of
the computational analysis tools used by the ENCODE Consor-
tium that are listed in Table 3. The name of each software tool
appears in the first column, and subsequent columns contain the
tasks for which the tool is used, the PMID reference number when
available, and a web address where the tool can be accessed.
(DOC)
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